These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15918994)

  • 1. Gut inflammation in the spondyloarthropathies.
    Mielants H; De Keyser F; Baeten D; Van den Bosch F
    Curr Rheumatol Rep; 2005 Jun; 7(3):188-94. PubMed ID: 15918994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment.
    Fragoulis GE; Liava C; Daoussis D; Akriviadis E; Garyfallos A; Dimitroulas T
    World J Gastroenterol; 2019 May; 25(18):2162-2176. PubMed ID: 31143068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies.
    Fantini MC; Pallone F; Monteleone G
    World J Gastroenterol; 2009 May; 15(20):2472-8. PubMed ID: 19468997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of intestinal inflammation in the pathogenesis of spondylarthropathies].
    Mielants H; Veys EM
    Verh K Acad Geneeskd Belg; 1996; 58(2):93-116. PubMed ID: 8768479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut inflammation and spondyloarthropathies.
    De Keyser F; Baeten D; Van den Bosch F; De Vos M; Cuvelier C; Mielants H; Veys E
    Curr Rheumatol Rep; 2002 Dec; 4(6):525-32. PubMed ID: 12427369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune linkages between inflammatory bowel disease and spondyloarthropathies.
    Baeten D; De Keyser F; Mielants H; Veys EM
    Curr Opin Rheumatol; 2002 Jul; 14(4):342-7. PubMed ID: 12118165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic and genetic links between spondylarthropathies and inflammatory bowel diseases.
    Faustini F; Zoli A; Ferraccioli GF
    Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():1-9. PubMed ID: 19530505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of spondylarthropathy in inflammatory bowel disease.
    Generini S; Fiori G; Matucci Cerinic M
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S88-94. PubMed ID: 12463455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The joint-gut axis in inflammatory bowel diseases.
    Brakenhoff LK; van der Heijde DM; Hommes DW; Huizinga TW; Fidder HH
    J Crohns Colitis; 2010 Sep; 4(3):257-68. PubMed ID: 21122514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current issues in pediatric inflammatory bowel disease-associated arthropathies.
    Cardile S; Romano C
    World J Gastroenterol; 2014 Jan; 20(1):45-52. PubMed ID: 24415857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of gut inflammation in the pathogenesis of spondyloarthropathies.
    Mielants H; De Vos M; Cuvelier C; Veys EM
    Acta Clin Belg; 1996; 51(5):340-9. PubMed ID: 8950841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current use of biologicals for the treatment of spondyloarthropathies.
    Keyser FD; Mielants H; Veys EM
    Expert Opin Pharmacother; 2001 Jan; 2(1):85-93. PubMed ID: 11336571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory bowel disease and spondylarthropathy.
    Smale S; Natt RS; Orchard TR; Russell AS; Bjarnason I
    Arthritis Rheum; 2001 Dec; 44(12):2728-36. PubMed ID: 11762932
    [No Abstract]   [Full Text] [Related]  

  • 14. Mucosal inflammation in spondylarthritides: past, present, and future.
    Van Praet L; Van den Bosch F; Mielants H; Elewaut D
    Curr Rheumatol Rep; 2011 Oct; 13(5):409-15. PubMed ID: 21744132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal lesions associated with spondyloarthropathies.
    Orlando A; Renna S; Perricone G; Cottone M
    World J Gastroenterol; 2009 May; 15(20):2443-8. PubMed ID: 19468992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease-associated spondyloarthropathies.
    Fries W
    World J Gastroenterol; 2009 May; 15(20):2441-2. PubMed ID: 19468991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seronegative spondyloarthropathy-associated inflammatory bowel disease.
    Wang CR; Tsai HW
    World J Gastroenterol; 2023 Jan; 29(3):450-468. PubMed ID: 36688014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.
    Verschueren P; Lensen F; Lerut E; Claes K; De Vos R; Van Damme B; Westhovens R
    Ann Rheum Dis; 2003 Apr; 62(4):368-9. PubMed ID: 12634242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.